12:00 AM
 | 
Feb 13, 2012
 |  BC Week In Review  |  Company News  |  Other News

United Therapeutics, Novartis cardiovascular, generics news

United Therapeutics received a Paragraph IV notification letter from Sandoz, the generics unit of Novartis, indicating that it submitted an ANDA to FDA for a generic version of United Therapeutics' 10 mg/ml Remodulin treprostinil injection. The Paragraph IV...

Read the full 177 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >